




INTUITIONLABS / RESEARCH & PRACTICAL GUIDANCE

FlowJo 11 vs OMIQ vs Cytobank: Biotech Pilot Guide

Build practical AI for pharma and biotech with IntuitionLabs. We help life-science teams turn complex information and workflows into useful software, governed knowledge systems and AI tools.

Published by IntuitionLabs · 2026-10-01 · flowjo 11 vs omiq vs cytobank · flow cytometry software · flowjo 11 · omiq · cytobank · spectral flow cytometry · fcs analysis · biotech software pilot

Original article: <https://intuitionlabs.ai/articles/flowjo-11-vs-omiq-vs-cytobank>



FlowJo 11 vs OMIQ vs Cytobank: Biotech Pilot Guide

intuitionlabs.ai

In this article

1. Executive Summary
 2. Introduction and Background
 3. FlowJo 11
 4. OMIQ
 5. Cytobank
 6. Feature Comparison
 7. Performance and Benchmarks
 8. Data Analysis and Evidence
 9. Implications and Future Directions
 10. Frequently Asked Questions (FAQs)
 11. Conclusion
-

Executive Summary

FlowJo 11, **OMIQ**, and **Cytobank** address the same research need from different operating models. FlowJo 11 is locally installed, uses BD Access Portal licensing, and accepts Flow Cytometry Standard (FCS) files from multiple instruments; its vendor labels it for research use only. (www.flowjo.com) (www.flowjo.com) OMIQ is browser based and publishes corporate starting prices of **\$2,000 per user per year** for Essentials and **\$3,750 per user per year** for Professional, with Enterprise priced by quotation. (www.omic.ai) (www.omic.ai) Cytobank Premium is a shared cloud subscription, while Enterprise provides a private cloud and administrator controls; Beckman also labels Cytobank for research use only. (www.beckman.com)

For a biotech laboratory, the choice turns on whether the system preserves the assay's scientific meaning and review evidence after import, transformation, compensation or spectral unmixing, gating, statistics, and export. FCS standardization facilitates exchange of event files, while Gating-ML addresses exchange of gates and transformations; neither by itself proves a complete project migrates intact. (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) The strongest pilot uses **one matched, blinded FCS set** and asks a second analyst to reproduce predefined results. A multicenter study found interlaboratory coefficients of variation from **1.8% to 102.1%** across populations and gating approaches, a reminder that analyst and protocol variation can dominate a software comparison. That study did not benchmark these products. (pmc.ncbi.nlm.nih.gov)

The most useful commercial distinction is documented capacity and control, rather than a generic feature count. OMIQ Essentials lists **50 GB per user** and **20 million events per dataset**; Professional lists **600 GB per user**, while Enterprise advertises dedicated deployment and expanded limits. (www.omic.ai) Cytobank Premium's default allocation is **500 GB**, and Enterprise storage is customized. (www.beckman.com) FlowJo's standard portal license allows a **24-hour** offline window after sign-in, subject to its licensing terms. These figures should be placed beside the laboratory's actual file sizes, user counts, retention period, and quotation, as of **October 2026**.

No independent, matched-panel head-to-head benchmark found in this research establishes a speed or accuracy winner among the three. The defensible decision is to score the same files and review tasks, then calculate a **three-year total cost of ownership** with quoted license, storage, integration, validation, and

support costs. Vendor descriptions of electronic signatures, audit trails, or GxP support are procurement inputs, not proof that a particular regulated workflow has been validated. FDA guidance ties Part 11 scope to qualifying electronic records and asks organizations to consider a system's effect on record accuracy and reliability. (www.fda.gov)

Introduction and Background

A flow cytometry analysis platform is part of a measurement chain, not merely a plotting application. The laboratory must define panel design, control material, instrument settings, FCS file identity, transformations, gates, population denominators, and the final reviewable output. The International Society for Advancement of Cytometry's MIFlowCyt standard describes the minimum information for reporting an experiment, and its FCS work includes metadata such as sample volume and plate or well information. (isac-net.org) A comparison that starts with screenshots alone can miss whether sample names, gates, and statistics still mean the same thing after migration.

The target reader may manage conventional multiparameter panels, spectral panels, longitudinal cohorts, cell-therapy assays, or other single-cell cytometry analyses. For spectral data, single-color reference controls and an unstained control belong in the pilot set; published workflow guidance calls for checking reference signatures before unmixing. (www.frontiersin.org) The test should include typical and difficult files, such as low-count populations, variable acquisition periods, and deliberately ambiguous metadata. These are proposed test conditions, not claims that any vendor fails them. The pilot should record the instrument, acquisition software, FCS version, panel revision, analyst, and intended output before software is opened.

The word **best** is therefore conditional. A group optimizing a familiar local gate review may weight desktop continuity heavily. A distributed translational team may weight shared access, permissions, and reproducible workflow handoff. A quality team may care most about retained records and evidence of approval. IntuitionLabs describes its own advisory approach as deciding what to scale from observed evidence and lists data engineering among its services; this is the publisher's general perspective and does not establish evidence about any cytometry platform. (intuitionlabs.ai) (intuitionlabs.ai) The recommendations below distinguish current vendor documentation from outcomes that only a buyer-run pilot can establish.

FlowJo 11

Capabilities

FlowJo v11.2 is the release identified on the current download page as of October 2026. The vendor documents traditional compensation, spectral unmixing, high-dimensional analysis, and support for FCS files from different acquisition systems. (www.flowjo.com) (www.flowjo.com) Its group model applies an operation to every sample in a group, and its table interface updates statistics as populations and samples are added. (flowjo.com) (www.flowjo.com) Those functions make a sensible starting point for a laboratory with established gate trees, but the pilot must still compare event membership and derived percentages on the same files. The integrated quality-control tool creates Good Events and Bad Events populations, which should be inspected and documented rather than accepted solely by name. (www.flowjo.com) CSV keyword import is another route for sample metadata, and the pilot should test whether identifiers match the source manifest. (www.flowjo.com)

Adoption

Version 11 uses **BD Access Portal** licensing, with the portal helper application running on the same computer as FlowJo. (www.flowjo.com) The vendor offers a **30-day trial**, an individual login model that permits one active computer at a time across up to **four computers**, and group licensing beginning at **five users**. (www.flowjo.com) Portal licenses renew annually. A standard license has a **24-hour** offline period after sign-in, and documented extended offline tokens can cover **14 days** on one device. (www.flowjo.com) Buyers should test authentication at instrument rooms, secure networks, and remote sites before treating offline work as solved.

Strengths and Limitations

The clearest continuity advantage is access to a familiar workspace and local analysis path. The migration boundary deserves a real test: FlowJo says v11 workbenches can be exported to v10 workspaces, but v11 tables, charts, and reports are not included in that export. (flowjo.com) Its v10-to-v11 import notes also state that tables were not imported in v11.2. (flowjo.com) A renewal decision should sample old workspaces, verify gates and transformations, rebuild representative reports, and retain both source and migrated outputs. FlowJo's research-use label also means a buyer must evaluate any regulated purpose separately. The reviewed public materials do not establish a vendor-neutral, matched-data performance advantage or a deployment-specific regulated-use validation package.

OMIQ

Capabilities

OMIQ describes a fully cloud-based analysis environment with no local installation. (www.omiq.ai) Its documented workflow captures gates, transformations, algorithms, and settings, and its feature page describes applying spillover compensation and spectral unmixing matrices. (www.omiq.ai) Manual gates apply to all files automatically, so the pilot should check how per-file exceptions, metadata groups, and revised gates are handled. (help.omiq.ai) Shared datasets and workflows have Reader and Editor roles; templates are documented as versioned and immutable. The vendor advertises import of FlowJo gating, while the help center explicitly documents CSV and FCS upload. The broader getting-started page also mentions LMD, so an LMD-dependent lab should confirm its actual import path in the current tenant rather than infer it from the marketing summary. (www.omiq.ai)

Adoption

The current corporate list prices are **\$2,000 per user per year** for Essentials and **from \$3,750 per user per year** for Professional. Essentials lists **50 GB** per user and up to **20 million events per dataset**; Professional lists **600 GB** per user and no stated event cap on the pricing page. (www.omiq.ai) Enterprise pricing is custom, with vendor-described dedicated deployment, single sign-on using SAML 2.0 or OIDC, and expanded storage and event limits. (www.omiq.ai) Those allowances are contractual starting points, not a throughput benchmark. An enterprise pilot should test upload, sharing, backup and retention expectations against the proposed order form.

Strengths and Limitations

OMIQ has a concrete collaboration and workflow-template story, and its help center says exports can be CSV or FCS. (help.omiq.ai) Its security page states that the shared production environment stores data in the United States, while a dedicated environment can be provisioned to customer requirements; it also describes encryption at rest. (www.omiq.ai) The pricing page advertises **GxP and 21 CFR Part 11 support** for Enterprise, and the help center limits electronic signatures to Enterprise clients. (help.omiq.ai) The signature process is described as creating an immutable log with time and signer details. A buyer should obtain the exact feature entitlement, configuration, evidence export, and vendor support scope in writing. None of those published claims alone validates a customer's particular assay, record policy, or intended use.

Cytobank

Capabilities

Cytobank Premium and **Cytobank Enterprise** are browser-based offerings. Beckman lists FCS **2.0, 3.0, and 3.1** support for Premium and names algorithms including FlowSOM, SPADE, viSNE, UMAP, and PeacoQC. (www.beckman.com) (www.beckman.com) The product documentation says an experiment-wide compensation matrix can feed downstream gates and analysis. (support.cytobank.org) Release notes describe gate synchronization across files and populations. (www.beckman.com) The support site documents gate import from other Cytobank experiments or Gating-ML, which gives the pilot a specific portability test. (support.cytobank.org) Its sample tags can be exported as a tab-separated spreadsheet, making metadata reconciliation testable. (support.cytobank.org)

Adoption

Premium is positioned for individuals or small groups on a **shared cloud**. Enterprise is positioned for larger research teams on a **private cloud** with an administrator dashboard, access monitoring, and dedicated computing resources. (www.beckman.com) The vendor lists academic and commercial licenses with **one- to three-year** terms, but the reviewed public pages did not establish a commercial Premium or Enterprise price. (www.beckman.com) Premium's default storage allocation is **500 GB**, while Enterprise allocation is customized. (www.beckman.com) The buyer's quotation should therefore identify users, storage, compute caps, retention, support, and the availability of optional controls, rather than using an invented per-seat figure.

Strengths and Limitations

Enterprise has a documented application programming interface (API) intended to connect with other information systems; Beckman specifically describes transfers to electronic laboratory notebooks (ELNs) as a possible integration. (www.beckman.com) The optional audit-trail feature is described as viewable and exportable to PDF, and optional sign-off functions assign review roles. (www.beckman.com) These are configuration and scope questions for procurement, not proof that every tenant has the same controls enabled. Cytobank can export FCS or CSV events, but its support page says transformations and channel selection are not available for FCS export. (support.cytobank.org) That limitation should be tested against the receiving pipeline's needs. Beckman's research-use label excludes diagnostic procedures. (www.beckman.com)

Feature Comparison

Table 1 brings the documented edition, deployment, capacity, and review distinctions into one procurement view. A blank public price means **quote required**, not zero cost. Every row should be checked against a current proposal and contract.

Option	Hosting and access	Seat and commercial basis	Published volume	Documented records and handoff
FlowJo 11	Local application with BD Access Portal authentication (www.flowjo.com)	Annual individual or group license; quote required	Depends on local hardware and file set; Windows guidance lists 16 GB RAM minimum (www.flowjo.com)	Workbench export to v10 omits v11 tables, charts, reports
OMIQ Essentials	Shared browser environment	\$2,000 corporate user/year	50 GB/user, 20 million events/dataset (www.omiq.ai)	Shared dataset and workflow permissions
OMIQ Professional	Browser environment	From \$3,750 corporate user/year (www.omiq.ai)	600 GB/user ; confirm all volume terms in quote	Versioned workflow templates
OMIQ Enterprise	Dedicated instance, SSO (www.omiq.ai)	Custom quote	Vendor says unlimited storage and events per dataset	Enterprise electronic signatures; confirm evidence export
Cytobank Premium	Shared cloud	Commercial quote; contract term to confirm	Default 500 GB storage (www.beckman.com)	FCS/CSV export, with documented FCS export constraints (support.cytobank.org)
Cytobank Enterprise	Private cloud, administrator controls (www.beckman.com)	Commercial quote; one- to three-year terms listed	Customized allocation and compute terms	API integration and optional audit and sign-off features

The matrix points to distinct pilot risks. FlowJo requires an authentication and migration check; OMIQ requires an event and storage fit check at the proposed tier; Cytobank requires edition-specific entitlement and integration proof. These are test priorities inferred from the published terms, not scores. For any platform, the procurement record should include the exact edition, region, version, support level, data export route, and retention policy. The format standard itself only ensures a common FCS container; it does not prove that annotations and analysis artifacts survive a round trip. (pmc.ncbi.nlm.nih.gov) (isac-net.org)

The current FCS standard also carries metadata that a laboratory can use as a reconciliation key. FCS 3.1 added plate and well identifiers and a keyword distinguishing original from altered files; FCS 3.2 added explicit dye, detector, and analyte keywords. (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov) A pilot should inspect these fields before and after import and export, then record any mapping needed for its laboratory information management system (LIMS) or ELN. The presence of a file extension is not an adequate metadata check.

Performance and Benchmarks

There is **no verified independent head-to-head benchmark** here using one controlled panel, hardware or cloud conditions, and scoring method across FlowJo 11, OMIQ, and Cytobank. Published time savings from other workflows must not be assigned to these products. For example, one research workflow reported **7 minutes per FCS file** for its manual procedure and **1.5 minutes per file** for its automated procedure across 24 cell subsets; that is a study-specific comparison, not a vendor ranking. (www.nature.com) A useful pilot records both elapsed analyst time and the quality of the resulting evidence.

A matched-data pilot protocol

Freeze a representative set of instrument-native FCS files and a manifest before inviting vendors to a demonstration. Include unstained and single-color controls, a full panel, biological replicates, a longitudinal or batch series, and files with a rare population. Spectral guidance supports checking the control signatures before unmixing, and published cytometry guidance recommends reviewing automatically supplied gates and results. (www.frontiersin.org) (pmc.ncbi.nlm.nih.gov) If no proprietary set can be shared, FlowRepository permits downloading annotated experiment files and attachments for a preliminary workflow test, but the final decision still needs the lab's own assays. (flowrepository.org) (flowrepository.org)

Table 2 is the results sheet. **Not tested** is the only honest outcome until the buyer runs the same set in all three products. Define tolerances before the demonstration, and preserve screen recordings or exports that let a second analyst confirm each result.

Test case and input	Acceptance evidence to capture	FlowJo 11	OMIQ	Cytobank
Import frozen FCS set and manifest	File count, checksums, FCS version, keywords, sample IDs	Not tested	Not tested	Not tested
Apply controls and transformations	Recorded matrix, reference controls, scale settings, transformed plots	Not tested	Not tested	Not tested
Gate full panel and rare subset	Gate coordinates, parent population, denominator, event membership	Not tested	Not tested	Not tested
Batch apply and revise	Propagation rule, exceptions, before and after statistics	Not tested	Not tested	Not tested
Run quality control	Flagged acquisition periods and analyst disposition	Not tested	Not tested	Not tested
Share and review	User roles, change history, approval artifact, evidence export	Not tested	Not tested	Not tested
Export and re-import	FCS or CSV, gate portability, metadata reconciliation, readable report	Not tested	Not tested	Not tested
Second-analyst reproduction	Independent result, discrepancy log, time and support burden	Not tested	Not tested	Not tested

The acceptance evidence should include **event membership**, not only similar-looking plots. Gating-ML was designed to encode gates and transformations in an application-independent form and to yield the same event populations when compliant tools apply the same definition to the same data. ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) That principle helps specify a portability test, although vendor support and analysis semantics still need checking. For statistics, MIFlowCyt calls for reporting the denominator of a gated percentage because changing the parent population changes the interpretation. (isac-net.org) The second analyst should work from the saved project and a written protocol, without undocumented verbal help from the first analyst.

Measure upload or load time, analysis time, export time, and time to resolve a discrepancy separately. Note local computer specifications and network conditions so a cloud-to-desktop comparison is reproducible. NIST identifies comparability across instrument platforms and times as a measurement challenge; one software stopwatch cannot replace the assay's control strategy. (www.nist.gov) A laboratory should use a blinded acceptance review for biologically important populations and document when an automated method needs a manual decision.

Data Analysis and Evidence

The available quantitative evidence supports **pilot design**, not a universal product ranking. In one multicenter study, seven laboratories used a shared staining protocol and local analysis; mean interlaboratory coefficients of variation ranged from **1.8% to 102.1%** across the evaluated populations and gating strategies. Central gating was the only tested approach with mean coefficients consistently below **25%**. ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) A separate high-dimensional study compared **23** clustering tools and found pairwise manual-rater agreement from **0.44 to 0.86** on its kappa measure. ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) These studies had their own panels and methods. Their relevance is that a buyer should lock the reference analysis and quantify analyst variability before interpreting small differences among software outputs.

A cell-therapy gating study found a **57%** reduction in between-participant variability when participants followed a diagrammatic protocol, with a **23%** reduction in its range of expanded measurement uncertainty. ([pmc.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/)) That observation supports giving every pilot analyst the same gate definitions, control decisions, and denominator rules. It does not predict a 57% improvement from any platform. For the pilot, calculate per-population absolute percentage-point difference, relative difference where the reference is nonzero, event-overlap measures where IDs are available, and a discrepancy rate per file. Report the sample count and confidence interval where repeated measurements justify one. Keep biological acceptance thresholds set by the assay owner.

Three-year ownership worksheet

Table 3 is a **reader-supplied**, three-year total cost of ownership (TCO) worksheet. It uses published OMIQ list prices as a check on one input, but every organization should replace list prices with signed quotations. No FlowJo or Cytobank commercial price is inferred.

Cost input	Reader entry or calculation	Evidence to request
Licensed users	Named users by edition and year	Seat definition, growth allowance, concurrent use

Cost input	Reader entry or calculation	Evidence to request
Annual subscription	Quoted annual rate × users × 3; use the published tier figures in Table 1 only as a preliminary baseline	Order form, renewal cap, tier and discount
Storage and compute	Three-year quoted allowance plus projected overage	FCS bytes, derived objects, retention, compute cap
Implementation and migration	One-time setup plus workbench rebuild and training	Vendor statement of work, internal analyst hours
Integration and validation	API or data pipeline work plus planned qualification	Interface scope, test evidence, change control
Support and exit	Three years of support plus export and archive costs	Support tier, response targets, termination rights
Three-year TCO	Sum of all rows; report low, expected, and high cases	Signed assumptions and date of quotation

The interpretation matters more than a single total. Storage allocations can make a low seat price unsuitable for a large high-dimensional archive, while an enterprise quote may bundle services omitted from a list price. OMIQ's published **50 GB**, **600 GB**, and **20-million-event** figures illustrate why the lab must model its largest datasets and projected retention explicitly. Cytobank's **500 GB** Premium default is a different capacity definition and should not be compared to a per-user OMIQ allowance without a workload model. (www.beckman.com) For FlowJo, local workstation, backup, and license-access costs belong in the same worksheet. FlowJo's documented Windows minimum of **16 GB RAM**, with **32 GB** recommended, is a hardware planning input, not a measured dataset limit.

Weighted decision score

Use a proposed **100-point** score with **30 points** for scientific concordance, **20** for repeatability and QC, **15** for collaboration and review, **15** for integration and export, **10** for security and access, and **10** for three-year TCO. These are editorial starting weights; assay owners should approve them before seeing a demo. Award each criterion zero to its weight using explicit acceptance evidence from Table 2. Record both a score and an unresolved-evidence flag. A vendor claim without a demonstrated artifact receives no experimental performance credit. The total should be accompanied by hard gates for required record retention, data residency, and minimum event volume, since a weighted average can otherwise hide an unacceptable deficiency.

Implications and Future Directions

The three options express a broader shift in cytometry analysis. FlowJo 11 brings high-dimensional methods and spectral unmixing into a locally installed workflow, while OMIQ and Cytobank put collaboration and centrally managed capacity into browser environments. The practical question is where the team wants to manage identity, files, settings, review evidence, and long-term access. A multi-site group should include an analyst at each site in the pilot and compare outputs across instruments and time points, consistent with NIST's emphasis on cross-platform comparability. (www.nist.gov)

Migration should be staged as a **record reconciliation exercise**. First, inventory source FCS files, panel versions, metadata keys, workspaces, report templates, and downstream interfaces. Second, import a frozen subset and compare event counts, transforms, gate membership, and denominators. Third, export the analysis and verify that another analyst can reconstruct the stated result. FlowJo's v11-to-v10 export excludes v11 reporting artifacts; OMIQ advertises FlowJo gate import; Cytobank documents Gating-ML gate import. Those are three different kinds of portability and should be tested separately. (support.cytobank.org) The final archive should retain the original files and the exact software and protocol version used for a reported result.

For any workflow that creates regulated electronic records, the buyer's quality team must determine scope, validation approach, access controls, signatures, retention, and the ability to produce faithful copies. FDA guidance says Part 11 applies to qualifying electronic records and recommends copies that preserve record content and meaning. (www.fda.gov) CLSI H62 covers flow cytometry assay processes through review and retention but explicitly places software validation outside its scope, reinforcing the need for a separate system assessment. (clsi.org) Vendor GxP support language is useful for vendor selection, but no general label substitutes for a documented intended-use assessment and implementation evidence.

The most valuable next data would be published, version-specific, matched-file comparisons of analysis time, gate concordance, audit export, and second-analyst reproduction. Until those exist, labs can create comparable internal evidence by publishing their file manifest, acceptance rules, and scores, subject to their confidentiality constraints. That is more transferable than a winner declared from feature lists.

Frequently Asked Questions (FAQs)

Which is best for a small biotech lab?

The answer depends on the lab's workflow. FlowJo 11 is a plausible first pilot for teams with established local workspaces; OMIQ Essentials has published corporate terms and defined event and storage limits; Cytobank Premium offers a shared cloud with a published default storage allocation. Run the same FCS set and compare the rework needed to produce the approved output.

Is OMIQ or Cytobank better for shared high-dimensional analysis?

Both document browser workflows and high-dimensional tools. OMIQ documents shared roles and versioned templates, while Cytobank Enterprise documents private-cloud administration and API integration. Test actual collaboration, security requirements, export, and quotation at the proposed edition. Neither vendor's feature list is a substitute for a controlled workload test.

Can these platforms be used for regulated clinical decisions?

FlowJo's research-use label says it is not for use in diagnostic or therapeutic procedures ([BD FlowJo v11 brochure](#)), and OMIQ's Enterprise page makes support claims for GxP and Part 11. Beckman labels Cytobank 'For Research Use Only. Not for use in diagnostic procedures.' The buyer must define intended use and assess the configured system and records under applicable requirements. A marketing claim is not a validation conclusion. For other regulated electronic-record workflows, FDA recommends determining whether specific records are Part 11 records based on the applicable predicate rules. (www.fda.gov)

Conclusion

A defensible FlowJo 11 vs OMIQ vs Cytobank decision starts with the laboratory's own assay and output requirements. FlowJo 11 offers a local, portal-licensed path with documented spectral analysis and workspace migration boundaries. OMIQ offers a browser workflow with published corporate tiers and enterprise controls. Cytobank offers shared and private cloud editions with documented integration and optional review features. Each is a candidate for research analysis, with different evidence still needed at procurement and validation time.

The recommended decision artifact is a frozen FCS set, a signed acceptance sheet, an observed results table, and a three-year cost worksheet. Score gate and statistic concordance, metadata preservation, QC dispositions, analyst reproduction, export, access, and support on that same material. Treat untested cells as unknown. Use edition-specific quotes and have the intended-use owner review any regulated record requirements. That process produces an auditable choice for the actual panel and team, even while independent product-to-product benchmarks remain unavailable. At each renewal, repeat the same acceptance tests with the current software version, a current panel, and the actual analyst group. Preserve the prior result as a baseline, record any changed assumptions, and revisit the weighting only when the assay or operating model changes. The result is a decision that can be explained and repeated.

Source links

Links cited in this article, in order of first appearance. Full addresses are provided for readers using extracted text.

1. <https://www.flowjo.com/flowjo/overview>
2. <https://www.flowjo.com/docs/flowjo11/license-info>
3. <https://www.omic.ai/series/getting-started>
4. <https://www.omic.ai/pricing>
5. <https://www.beckman.com/flow-cytometry/software/cytobank-premium/premium-v-enterprise>
6. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2892967/>
7. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4874733/>
8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC5717516/>
9. <https://www.omic.ai/enterprise>
10. <https://www.beckman.com/flow-cytometry/software/cytobank-premium/storage>
11. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application?lng=en-US&ss=page_is-an-electronic-signature-legal_undefined
12. <https://isac-net.org/data-standards/>
13. <https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2020.612801/full>
14. <https://intuitionlabs.ai/>
15. <https://www.flowjo.com/flowjo/download>
16. <https://flowjo.com/docs/flowjo11/welcome-version-11/primary-components-2>
17. <https://www.flowjo.com/docs/flowjo11/tables-2>
18. <https://www.flowjo.com/docs/flowjo11/sample-quality-control-2-2>

19. <https://www.flowjo.com/docs/flowjo11/metadata-manager-2-2/keywords-2>
20. <https://www.flowjo.com/flowjo/quote-request>
21. <https://www.flowjo.com/docs/flowjo11/license-info/extended-offline-tokens>
22. <https://flowjo.com/docs/flowjo11/welcome-version-11/compatibility>
23. <https://flowjo.com/docs/flowjo11/welcome-version-11/v10-workspace-import>
24. <https://www.omic.ai/features/flow-cytometry-software>
25. <https://help.omic.ai/hc/en-us/articles/35566619301396-Performing-Manual-Gating-in-OMIQ>
26. <https://help.omic.ai/hc/en-us/articles/34928824426644-How-to-Export-Data-From-OMIQ>
27. <https://www.omic.ai/security>
28. <https://help.omic.ai/hc/en-us/articles/43501761025812-Using-Electronic-Signatures-in-OMIQ>
29. <https://www.beckman.com/flow-cytometry/software/cytobank-premium>
30. <https://support.cytobank.org/hc/en-us/articles/360049334512-How-the-experiment-wide-compensation-works-in-the-Cytobank-platform>
31. <https://www.beckman.com/flow-cytometry/software/cytobank-premium/release-notes>
32. <https://support.cytobank.org/hc/en-us/articles/204765618-Exporting-and-Importing-Gates-within-Cytobank-and-with-Gating-ML>
33. <https://support.cytobank.org/hc/en-us/articles/206481047-How-to-annotate-data-with-sample-tags-in-the-Cytobank-platform-tutorial>
34. <https://www.beckman.com/flow-cytometry/software/cytobank-enterprise>
35. <https://www.beckman.com/flow-cytometry/software/cytobank-enterprise/api>
36. <https://support.cytobank.org/hc/en-us/articles/205201928-Export-data-as-FCS-or-spreadsheet-files-from-whole-files-and-or-gated-populations>
37. <https://pubmed.ncbi.nlm.nih.gov/32881398/>
38. <https://www.nature.com/articles/s41598-020-65016-x>
39. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7350392/>
40. <https://flowrepository.org/>
41. https://flowrepository.org/help_topics/MIFlowCyt_public_experiment_downloads.html
42. <https://www.nist.gov/programs-projects/quantitative-flow-cytometry-measurements>
43. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11630031/>
44. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8103269/>
45. <https://clsi.org/shop/standards/h62/>
46. https://info.flowjo.com/hubfs/FlowJo%20v11/BD-152556_FlowJov11_Overview_Brochure_DIGITAL.pdf

THE PUBLISHER

About IntuitionLabs

IntuitionLabs is an AI consulting, custom software development and data engineering firm serving pharmaceutical, biotechnology, medical-device and other life-science organizations. We work with clinical, regulatory, medical-affairs, commercial, quality and IT teams to connect technology decisions with the work people need to accomplish.

AI consulting and adoption

Our AI enablement services cover readiness assessments, use-case selection, governance and policies, team workshops, adoption measurement and ongoing advisory support. We help organizations structure the information layer behind AI: source material, context, permissions and maintained knowledge that make generated answers useful and reviewable. Private LLM inference and hosted AI options support teams evaluating how to operate AI with appropriate control over their data and infrastructure.

Software, data and life-science workflows

IntuitionLabs develops custom software for pharma and biotech, integrates enterprise systems, and builds data engineering and business intelligence solutions. Areas of focus include AI agents, regulatory research, medical writing, medical affairs, CMC information, competitive intelligence and clinical-document workflows. Our eTMF intelligence work includes cross-system reconciliation and inspection-readiness support.

Enterprise platforms and regulated delivery

We provide Veeva services, application support, managed services, integrations and custom applications, alongside enterprise content work involving platforms such as Egnyte. For regulated workflows, our services include GxP enablement, computer-system validation and software development addressing 21 CFR Part 11 requirements. The applicable controls, validation responsibilities and acceptance criteria are defined for each engagement.

Work with IntuitionLabs

Explore [AI enablement](#), [pharma and biotech software development](#), [data engineering and BI](#), and [Veeva services](#). [Contact IntuitionLabs](#) to discuss your workflow, information sources and implementation needs.

IntuitionLabs publishes educational research to help life-science teams make informed technology decisions. Coverage of a product or organization does not imply a client relationship, endorsement or partnership.

Website: <https://intuitionlabs.ai>

This article is educational. Verify consequential medical, legal, financial, regulatory and technical decisions with appropriate professionals and the cited primary sources. Company services are described separately from the article's research findings.